Jonathan Aschoff
Stock Analyst at Roth MKM
(0.63)
# 3,828
Out of 4,761 analysts
43
Total ratings
23.08%
Success rate
-32.4%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GTBP GT Biopharma | Initiates: Buy | $11 | $2.15 | +411.63% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $7.68 | +173.44% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $555 → $296 | $3.47 | +8,430.26% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.80 | +900.00% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $17 | $1.30 | +1,207.69% | 2 | Aug 13, 2024 | |
| OTRK Ontrak | Maintains: Buy | $60 → $45 | $1.59 | +2,726.63% | 2 | Aug 9, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $20 | $1.67 | +1,097.60% | 1 | Jul 16, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Maintains: Buy | $21 → $11 | $0.34 | +3,135.29% | 2 | May 3, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $40 | $1.28 | +3,025.00% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $20 → $28 | $0.31 | +8,891.65% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $36 | $7.63 | +371.82% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $24 | $0.54 | +4,360.97% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $6.75 | +344.44% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $4.43 | +4,414.67% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $1.76 | +695.45% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2,400 → $7,200 | $4.31 | +166,953.36% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $0.68 | +1,076.47% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $5.40 | +1,751.85% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $1.11 | +35,936.04% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $4.52 | +740.71% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $480 | $0.16 | +305,632.48% | 1 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $2.24 | +4,185.71% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $8.59 | +51.34% | 1 | Dec 19, 2019 |
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $2.15
Upside: +411.63%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $7.68
Upside: +173.44%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $555 → $296
Current: $3.47
Upside: +8,430.26%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.80
Upside: +900.00%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $17
Current: $1.30
Upside: +1,207.69%
Ontrak
Aug 9, 2024
Maintains: Buy
Price Target: $60 → $45
Current: $1.59
Upside: +2,726.63%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $1.67
Upside: +1,097.60%
Cyclacel Pharmaceuticals
May 3, 2024
Maintains: Buy
Price Target: $21 → $11
Current: $0.34
Upside: +3,135.29%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $1.28
Upside: +3,025.00%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $20 → $28
Current: $0.31
Upside: +8,891.65%
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $7.63
Upside: +371.82%
Mar 5, 2024
Maintains: Buy
Price Target: $5 → $24
Current: $0.54
Upside: +4,360.97%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $6.75
Upside: +344.44%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $4.43
Upside: +4,414.67%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $1.76
Upside: +695.45%
Feb 14, 2023
Maintains: Buy
Price Target: $2,400 → $7,200
Current: $4.31
Upside: +166,953.36%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $0.68
Upside: +1,076.47%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $5.40
Upside: +1,751.85%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $1.11
Upside: +35,936.04%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $4.52
Upside: +740.71%
Feb 12, 2021
Initiates: Buy
Price Target: $480
Current: $0.16
Upside: +305,632.48%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $2.24
Upside: +4,185.71%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $8.59
Upside: +51.34%